Inhibition of aldose reductase ameliorates alcoholic liver disease by activating AMPK and modulating oxidative stress and inflammatory cytokines.
Level 5 - mechanism / opinion, no new human data
Preclinical animal and cell-culture mechanistic study.
PubMed 28677809 · doi:10.3892/mmr.2017.6895
What was done
Researchers evaluated the role of aldose reductase (AR) in alcoholic liver disease using in vivo and in vitro models. C57BL/6 mice were fed a Lieber-DeCarli liquid diet to induce alcoholic fatty liver disease, and mice were treated with the AR inhibitor zopolrestat. In vitro, mouse AML12 hepatocytes were exposed to ethanol and treated with the inhibitor. Outcomes measured included hepatic steatosis, lipid peroxidation, CYP2E1 expression, AMPK phosphorylation, and pro-inflammatory cytokine expression (TNF-α, IL-6, TGF-β1).
What was found
The abstract reports no numerical values or effect sizes. Ethanol diet increased AR protein expression in mice and in AML12 cells. Zopolrestat attenuated ethanol-induced hepatic steatosis in mice, associated with decreased hepatic lipoperoxides, decreased CYP2E1 protein expression, increased AMPK phosphorylation, and decreased TNF-α mRNA. In ethanol-treated AML12 cells, AR inhibition reduced lipid accumulation and oxidative stress, activated AMPK, and decreased mRNA expression of TNF-α, IL-6, and TGF-β1.
Why it matters
This study identifies aldose reductase as a potential mechanistic driver of ethanol-induced liver injury and suggests AR inhibition as a candidate target for therapeutic research in alcoholic liver disease.
Limits
The study is entirely preclinical, relying on mice and a mouse cell line, so findings may not translate directly to humans. The abstract omits sample sizes, exact effect sizes, drug concentrations/doses, and statistical confidence intervals.
Cited by
- supports In animal models, blocking fructose metabolism or blocking aldose reductase prevents alcohol-induced fatty liver disease.